

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation							
1. Given Name (First Name) Bruce	2. Surnar Sands	ne (Last Nar	ne)		3. Date 26-December-2016			
4. Are you the corresponding author?	✓ Yes	No						
5. Manuscript Title 2016-2017_ECCO_Annual_Disclosure								
6. Manuscript Identifying Number (if you know it)								
Section 2. The Work Under Co	onsidera	tion for P	ublication					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.								
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
AbbVie	√	✓			Consulting			
AGA Institute		✓			For role as Associate Editor of Gastroenterology			
Akros Pharma		✓			Consulting			
American Academy of CME, Inc.		✓			Honoraria for speaking in a CME program			
American College of Gastroenterology		✓			Honoraria for speaking in a CME program			
Amgen	✓	✓			Consulting			
Arena Pharmaceuticals		✓			Consulting			
AstraZeneca LP	✓	\checkmark			Consulting			
Boehringer-Ingelheim		✓			Consulting			
Bristol-Myers Squibb		\checkmark			Consulting			
Catrille & Associates, LLC		✓			Honoraria for speaking in a CME program			
Celgene	✓	✓			Consulting			



Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Cowen Services Company, LLC		✓			Consulting
Creative Educational Concepts, Inc.		✓			Honoraria for speaking in a CME program
Curatio CME Institute		✓			Honoraria for speaking in a CME program
Focus Medical Communications		✓			Honoraria for speaking in a CME program
Forest Research Institute		✓			Consulting
Allergan		✓			Consulting
Forward Pharma		✓			Consulting
MEDEX		✓			Honoraria for speaking in a CME program
mmune Pharmaceuticals		✓			Consulting
lanssen	✓	✓			Consulting
illy		✓			Consulting
uitpold Pharmaceuticals		✓			Consulting
Med-IQ, LLC		✓			Honoraria for speaking in a CME program
MedImmune	✓	✓			Consulting
Pfizer	✓	✓			Consulting
Prometheus Laboratories	✓	✓			Consulting
Receptos, Inc.		✓			Consulting
Rockpointe, Inc.		✓			Honoraria for speaking in a CME program
Salix Pharmaceuticals		\checkmark			Consulting
Scripps		/			Honoraria for speaking in a CME program
Shire		✓			Consulting
Strategic Consultants International		✓			Consulting
Synergy Pharmaceuticals		✓			Consulting
Fakeda	✓	✓			Consulting
Theravance Biopharma R&D, Inc.		✓			Consulting
li Genix		✓			Consulting
TopiVert Pharma		✓			Consulting



JCB			V			Consulting	
edanta Biosciences, Inc.			<u>.</u>			Consulting	
	dico Medical Education Honoraria for speaking in a CME program						
Section 3.	Relevant financial a	activities	outside 1	the submitted y	work.		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo							
Section 4. Intellectual Property Patents & Copyrights							
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No							
Section 5.	Relationships not	covered a	bove				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the follo	wing relationships/cond	ditions/circ	umstance	s are present (exp	olain bel	ow):	
✓ No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Sands reports grants and personal fees from AbbVie, personal fees from AGA Institute, personal fees from Akros Pharma, personal fees from American Academy of CME, Inc., personal fees from American College of Gastroenterology, grants and personal fees from American Pharmaceuticals, grants and personal fees from AstraZeneca LP, personal fees from Boehringer-Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from Catrille & Associates, LLC, grants and personal fees from Celgene, personal fees from Cowen Services Company, LLC, personal fees from Creative Educational Concepts, Inc., personal fees from Curatio CME Institute, personal fees from Focus Medical Communications, personal fees from Forest Research Institute, personal fees from Allergan, personal fees from Forward Pharma, personal fees from IMEDEX, personal fees from Immune Pharmaceuticals, grants and personal fees from Janssen, personal fees from Lilly, personal fees from Luitpold Pharmaceuticals, personal fees from Med-IQ, LLC, grants and personal fees from MedImmune, grants and personal fees from Prometheus Laboratories, personal fees from Receptos, Inc., personal fees from Sockpointe, Inc., personal fees from Salix Pharmaceuticals, personal fees from Scripps, personal fees from Shire, personal fees from Strategic Consultants International, personal fees from Synergy Pharmaceuticals, grants and personal fees from Takeda, personal fees from Theravance Biopharma R&D, Inc., personal fees from TiGenix, personal fees from TopiVert Pharma, personal fees from UCB, personal fees from Vedanta Biosciences, Inc., personal fees from Vindico Medical Education.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.